MicroRNA-17-5p-activated Wnt/β-catenin pathway contributes to the progression of liver fibrosis

Oncotarget

Volumn 7, Issue 1, 2016, Pages 81-93

  Yu, Fujun ^a   Lu, Zhongqiu ^a   Huang, Kate ^a   Wang, Xiaodong ^a   Xu, Ziqiang ^a   Chen, Bicheng ^a   Dong, Peihong ^a   Zheng, Jianjian ^a  

^a THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Hepatic stellate cells; microRNA 17 5p; Pathology section; Salvianolic acid B; Wnt inhibitory factor 1 (WIF1); Wnt catenin pathway

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BETA CATENIN; COLLAGEN TYPE 1; MICRORNA; MICRORNA 17 5P; PROTEIN INHIBITOR; SALVIANOLIC ACID B; UNCLASSIFIED DRUG; WNT INHIBITORY FACTOR 1; WNT PROTEIN; 3' UNTRANSLATED REGION; BENZOFURAN DERIVATIVE; CARBON TETRACHLORIDE; HERBACEOUS AGENT; MIRN17 MICRORNA, RAT; SCLEROPROTEIN; SIGNAL PEPTIDE; WIF1 PROTEIN, RAT;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC EFFECT; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CARBON TETRACHLORIDE-INDUCED LIVER CIRRHOSIS; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; HEPATIC STELLATE CELL; HSC-T6 CELL LINE; IN VITRO STUDY; IN VIVO STUDY; LIVER FIBROSIS; LUCIFERASE ASSAY; MALE; NONHUMAN; RAT; SPRAGUE DAWLEY RAT; WNT SIGNALING; 3' UNTRANSLATED REGION; ANIMAL; CELL CULTURE; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETICS; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; METABOLISM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING; WNT SIGNALING PATHWAY;

3' UNTRANSLATED REGIONS; ANIMALS; BENZOFURANS; BLOTTING, WESTERN; CARBON TETRACHLORIDE; CELL LINE; CELLS, CULTURED; DISEASE PROGRESSION; DRUGS, CHINESE HERBAL; EXTRACELLULAR MATRIX PROTEINS; GENE EXPRESSION REGULATION; HEPATIC STELLATE CELLS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LIVER CIRRHOSIS; MALE; MICRORNAS; MICROSCOPY, FLUORESCENCE; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY;

EID: 84964786536     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/ONCOTARGET.6447     Document Type: Article

References (40)

1. Hernandez-Gea V and Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol. 2011; 6:425-456
2. Wei J, Feng L, Li Z, Xu G and Fan X. MicroRNA-21 activates hepatic stellate cells via PTEN/Akt signaling. Biomed Pharmacother. 2013; 67:387-392
3. Tu X, Zhang H, Zhang J, Zhao S, Zheng X, Zhang Z, Zhu J, Chen J, Dong L and Zang Y. MicroRNA-101 suppresses liver fibrosis by targeting the TGFbeta signalling pathway. J Pathol. 2014; 234:46-59
4. He Y, Huang C, Sun X, Long XR, Lv XW and Li J. MicroRNA-146a modulates TGF-beta1-induced hepatic stellate cell proliferation by targeting SMAD4. Cell Signal. 2012; 24:1923-1930
5. Cheng JH, She H, Han YP, Wang J, Xiong S, Asahina K and Tsukamoto H. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol. 2008; 294:G39-49
6. Kim KK, Wei Y, Szekeres C, Kugler MC, Wolters PJ, Hill ML, Frank JA, Brumwell AN, Wheeler SE, Kreidberg JA and Chapman HA. Epithelial cell alpha3beta1 integrin links beta-catenin and Smad signaling to promote myofibroblast formation and pulmonary fibrosis. J Clin Invest. 2009; 119:213-224
7. Kordes C, Sawitza I and Haussinger D. Canonical Wnt signaling maintains the quiescent stage of hepatic stellate cells. Biochem Biophys Res Commun. 2008; 367:116-123
8. Jiang F, Parsons CJ and Stefanovic B. Gene expression profile of quiescent and activated rat hepatic stellate cells implicates Wnt signaling pathway in activation. J Hepatol. 2006; 45:401-409
9. Bovolenta P, Esteve P, Ruiz JM, Cisneros E and Lopez-Rios J. Beyond Wnt inhibition: new functions of secreted Frizzled-related proteins in development and disease. J Cell Sci. 2008; 121:737-746
10. Mao B, Wu W, Davidson G, Marhold J, Li M, Mechler BM, Delius H, Hoppe D, Stannek P, Walter C, Glinka A and Niehrs C. Kremen proteins are Dickkopf receptors that regulate Wnt/beta-catenin signalling. Nature. 2002; 417:664-667
11. Croce CM and Calin GA. miRNAs, cancer, and stem cell division. Cell. 2005; 122:6-7
12. Ghildiyal M and Zamore PD. Small silencing RNAs: an expanding universe. Nat Rev Genet. 2009; 10:94-108
13. Yang X, Du WW, Li H, Liu F, Khorshidi A, Rutnam ZJ and Yang BB. Both mature miR-17-5p and passenger strand miR-17-3p target TIMP3 and induce prostate tumor growth and invasion. Nucleic Acids Res. 2013; 41:9688-9704
14. Shan SW, Fang L, Shatseva T, Rutnam ZJ, Yang X, Du W, Lu WY, Xuan JW, Deng Z and Yang BB. Mature miR-17-5p and passenger miR-17-3p induce hepatocellular carcinoma by targeting PTEN, GalNT7 and vimentin in different signal pathways. J Cell Sci. 2013; 126:1517-1530
15. Cloonan N, Brown MK, Steptoe AL, Wani S, Chan WL, Forrest AR, Kolle G, Gabrielli B and Grimmond SM. The miR-17-5p microRNA is a key regulator of the G1/S phase cell cycle transition. Genome Biol. 2008; 9:R127
16. Yu F, Guo Y, Chen B, Dong P and Zheng J. MicroRNA 17-5p activates hepatic stellate cells through targeting of Smad7. Lab Invest. 2015; 95:781-789
17. Liu C, Liu P, Liu CH, Zhu XQ and Ji G. Effects of Fuzhenghuayu decoction on collagen synthesis of cultured hepatic stellate cells, hepatocytes and fibroblasts in rats. World J Gastroenterol. 1998; 4:548-549
18. Liu C, Jiang C, Liu P and Hu Y. [Intervention of Fuzhenghuayu decoction on autocrine activation of hepatic stellate cells]. Zhonghua Gan Zang Bing Za Zhi. 2001; 9:282-284
19. Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT and Zhang ZQ. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol. 2002; 8:679-685
20. Li S, Wang L, Yan X, Wang Q, Tao Y, Li J, Peng Y, Liu P and Liu C. Salvianolic Acid B Attenuates Rat Hepatic Fibrosis via Downregulating Angiotensin II Signaling. Evid Based Complement Alternat Med. 2012; 2012:160726
21. Zhao JF, Liu CH, Hu YY, Xu LM, Liu P and Liu C. Effect of salvianolic acid B on Smad3 expression in hepatic stellate cells. Hepatobiliary Pancreat Dis Int. 2004; 3:102-105
22. Guo Y, Xiao L, Sun L and Liu F. Wnt/beta-catenin signaling: a promising new target for fibrosis diseases. Physiol Res. 2012; 61:337-346
23. Kim TH, Kim SH, Seo JY, Chung H, Kwak HJ, Lee SK, Yoon HJ, Shin DH, Park SS and Sohn JW. Blockade of the Wnt/beta-catenin pathway attenuates bleomycin-induced pulmonary fibrosis. Tohoku J Exp Med. 2011; 223:45-54
24. He Y, Huang C, Zhang SP, Sun X, Long XR and Li J. The potential of microRNAs in liver fibrosis. Cell Signal. 2012; 24:2268-2272
25. Lin J and Chen A. Activation of peroxisome proliferatoractivated receptor-gamma by curcumin blocks the signaling pathways for PDGF and EGF in hepatic stellate cells. Lab Invest. 2008; 88:529-540
26. Wang R, Yu XY, Guo ZY, Wang YJ, Wu Y and Yuan YF. Inhibitory effects of salvianolic acid B on CCl(4)-induced hepatic fibrosis through regulating NF-kappaB/IkappaBalpha signaling. J Ethnopharmacol. 2012; 144:592-598
27. Tao YY, Wang QL, Shen L, Fu WW and Liu CH. Salvianolic acid B inhibits hepatic stellate cell activation through transforming growth factor beta-1 signal transduction pathway in vivo and in vitro. Exp Biol Med (Maywood). 2013; 238:1284-1296
28. Li L, He L, Zhao JL, Xiao J, Liu M, Li X and Tang H. MiR-17-5p up-regulates YES1 to modulate the cell cycle progression and apoptosis in ovarian cancer cell lines. J Cell Biochem. 2015; 116:1050-1059
29. Yang F, Yin Y, Wang F, Wang Y, Zhang L, Tang Y and Sun S. miR-17-5p Promotes migration of human hepatocellular carcinoma cells through the p38 mitogen-activated protein kinase-heat shock protein 27 pathway. Hepatology. 2010; 51:1614-1623
30. Peng H, Ishida M, Li L, Saito A, Kamiya A, Hamilton JP, Fu R, Olaru AV, An F, Popescu I, Iacob R, Dima S, Alexandrescu ST, Grigorie R, Nastase A, Berindan-Neagoe I, et al. Pseudogene INTS6P1 regulates its cognate gene INTS6 through competitive binding of miR-17-5p in hepatocellular carcinoma. Oncotarget. 2015; 6:5666-5677. Doi: 10.18632/oncotarget.3290
31. Zheng J, Dong P, Gao S, Wang N and Yu F. High expression of serum miR-17-5p associated with poor prognosis in patients with hepatocellular carcinoma. Hepatogastroenterology. 2013; 60:549-552
32. Weiskirchen R and Gressner AM. Isolation and culture of hepatic stellate cells. Methods Mol Med. 2005; 117:99-113
33. Yao QY, Xu BL, Wang JY, Liu HC, Zhang SC and Tu CT. Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complement Altern Med. 2012; 12:156
34. Chan LK, Chiu YT, Sze KM and Ng IO. Tensin4 is upregulated by EGF-induced ERK1/2 activity and promotes cell proliferation and migration in hepatocellular carcinoma. Oncotarget. 2015; 6: 20964-76. Doi: 10.18632/oncotarget.4122
35. Zheng J, Wu C, Xu Z, Xia P, Dong P, Chen B and Yu F. Hepatic stellate cell is activated by microRNA-181b via PTEN/Akt pathway. Mol Cell Biochem. 2015; 398:1-9
36. Kawahara T, Kashiwagi E, Ide H, Li Y, Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H and Miyamoto H. Cyclosporine A and tacrolimus inhibit bladder cancer growth through downregulation of NFATc1. Oncotarget. 2015; 6:1582-1593. Doi: 10.18632/oncotarget.2750
37. Zheng J, Wu C, Lin Z, Guo Y, Shi L, Dong P, Lu Z, Gao S, Liao Y, Chen B and Yu F. Curcumin up-regulates phosphatase and tensin homologue deleted on chromosome 10 through microRNA-mediated control of DNA methylation-a novel mechanism suppressing liver fibrosis. FEBS J. 2014; 281:88-103
38. Schmittgen TD and Livak KJ. Analyzing real-time PCR data by the comparative C(T) method. Nat Protoc. 2008; 3:1101-1108
39. Hua HW, Jiang F, Huang Q, Liao Z and Ding G. MicroRNA-153 promotes Wnt/beta-catenin activation in hepatocellular carcinoma through suppression of WWOX. Oncotarget. 2015; 6:3840-3847. Doi: 10.18632/oncotarget.2927
40. Kushwaha D, Ramakrishnan V, Ng K, Steed T, Nguyen T, Futalan D, Akers JC, Sarkaria J, Jiang T, Chowdhury D, Carter BS and Chen CC. A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA in glioblastomas. Oncotarget. 2014; 5:4026-4039. Doi: 10.18632/oncotarget.1974